JHVEPhoto/iStock Editorial via Getty Images
Replimune (REPL) shares more than doubled in post-market trading on Thursday after the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted in favor of the company’s lead asset, RP1.
The favorable voting comes ahead of an August 2 target
